Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)

CompletedOBSERVATIONAL
Enrollment

115

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

December 19, 2018

Study Completion Date

December 19, 2018

Conditions
Diabetic Macular Edema
Interventions
DRUG

dexamethasone intravitreal implant

Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.

Trial Locations (25)

13008

Clinique Monticelli, Marseille

13090

Centre MGM, Aix-en-Provence

13385

Hopital de la Timone, Marseille

29200

CHU Brest, Brest

31059

Chu Toulouse, Toulouse

33000

Centre Rétine Gallien à Bordeaux, Bordeaux

CHU Bordeaux, Bordeaux

41016

CH BLOIS, Blois

44800

Centre OPHTA.Kervision, Saint-Herblain

56100

CH SCORFF - Lorient, Lorient

67000

Maison Rouge, Strasbourg

69004

Hopital De La Croix Rousse, Lyon

74370

CHR Annecy, Metz-Tessy

75012

Chno 1520, Paris

75014

Hopital Saint Joseph, Paris

75019

Fondation Rothschild, Paris

75475

Lariboisiere, Paris

75679

COCHIN, Paris

78100

Hopital Saint Germain en Laye, Saint-Germain-en-Laye

78300

Hopital Poissy, Poissy

86021

Hôpital de La Milétrie Poitiers, Poitiers

93000

CH Avicennes Bobigny, Bobigny

93600

Ballanger, Aulnay-sous-Bois

94000

CHI Créteil, Créteil

06001

CHU Pasteur 2, Nice

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03003416 - Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME) | Biotech Hunter | Biotech Hunter